Experimental mobile app helps manage migraines
(Reuters Health) – A smartphone-based relaxation app could help migraine sufferers reduce the number of headaches they get each month, a small study suggests. Using the app twice a week…
FDA approves Lilly’s migraine drug as first ever cluster headache treatment
NEW YORK (Reuters) – Eli Lilly and Co’s migraine treatment Emgality on Tuesday became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks,…
U.S. regulator approves Teva migraine drug, shares rise
(Reuters) – Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the U.S. Food and Drug Administration (FDA) approved the company’s new…
U.S. medical device firm electroCore IPO price set at $15 per share
(Reuters) – U.S. medical device maker electroCore Llc’s initial public offering is expected to price at $15 per share, Chief Executive Officer Frank Amato told Reuters on Thursday. ElectroCore, which…
Novartis readies anti-sexism message for migraine drug
ZURICH (Reuters) – With women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to counteract sexism that it worries might become a barrier to…
Allergan migraine drug succeeds in second late-stage trial
NEW YORK (Reuters) – Allergan Plc on Friday announced positive results from a second Phase III trial for the 50 milligram dose of its drug for acute migraine, reproducing results…
Biohaven plunges as investors pit migraine data against Allergan’s drug
(Reuters) – Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from…